---

**From:** Lance Foster <burnettscott@example.org>  
**To:** Charlene Rios <qwolfe@example.net>  
**Subject:** Coordination on the Q4 Immunotherapy Rollout  

Hi Charlene,

I hope this message finds you well. As we gear up for the Q4 rollout of our new immunotherapy treatment, I wanted to touch base with you to discuss the latest findings from the clinical trials and how we can effectively communicate these to our healthcare partners.

Could we schedule a time next week to go over the data and strategize our approach? I'm particularly interested in your insights on how we can position the treatment's efficacy and safety profile to resonate with oncologists. My calendar is open on Tuesday and Thursday afternoon. Let me know what works for you.

Also, just a heads up, I'll be out of the office the week of November 13th for a conference but will be available via email for anything urgent.

Looking forward to our collaboration on this.

Best,  
Lance Foster  
Medical Sales Representative  
Merck & Co., Inc.  
Phone: (555) 123-4567  

---

**From:** Charlene Rios <qwolfe@example.net>  
**To:** Lance Foster <burnettscott@example.org>  
**Subject:** Re: Coordination on the Q4 Immunotherapy Rollout  

Hi Lance,

Thanks for reaching out. I agree that it's crucial we align on how we present the clinical data to our partners. I've reviewed the latest trial results, and there's some compelling data on patient response rates that could be a key selling point.

I'm available on Thursday afternoon; let's lock in a meeting at 3 PM. We can meet in my office at the R&D building, Room 407. Please bring any materials you think would be helpful for our discussion.

Safe travels to the conference! We can touch base on any developments that come up while you're away. 

Best regards,  
Charlene Rios  
Immunologist  
Merck & Co., Inc.  
Phone: (555) 987-6543  

---